Skip to main content

Modern Pathology

Original release date:
April 28, 2020
Access to this course expires on:  February 16, 2023 at 11:59 PM Pacific Time
CME 16.75

Course Description
The "play" on Modern Pathology, USCAP's high-impact anatomic pathology journal, is timed to highlight transition in Editors-in-Chief with exposition of some highly-cited papers by selected authors whose presentations will be memorialized for exposure on USCAP and Springer Nature websites. The educational content varies from sessions on genomics, informatics and personalized medicine to interactive microscopy and "what's hot in surgical pathology". USCAP is transforming not only how we learn but where we learn. This is an exceptional course with a panorama of new information.

Target Audience
Practicing academic and community pathologists, and pathologists-in-training

Learning Objectives
Upon completion of this educational activity, learners will be able to:
  • Understand fundamental concepts in molecular pathology, including their role in surgical pathology diagnoses and what pathologists should be able to communicate to clinicians
  • Become conversant with informatics concepts that modern pathologists should know
  • Improve diagnostic skills when assessing surgical specimens by interactive mentoring at multi-head microscopes with established experts in subspecialty areas, referencing new information in genetics and molecular pathology
  • Comprehend and be able to communicate the clinical relevance of pathology in the era of personalized medicine
  • Maximize peer-reviewed published papers as a resource for practice excellence

Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 16.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Beginning in 2021, the American Board of Pathology (ABPath) will no longer require Self-Assessment Modules (SAMs) for Part II Lifelong Learning of the Continuing Certification program. For additional information, visit the ABPath website.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:
  • Robert Anders: Advisory Board Member, Merck SD, Bristol Myers Squibb, AstraZeneca, Incyte; Grant or Research Support, FLX Bio
  • Liron Pantanowitz: Advisory Board Member, Leica, Hologic, Ibex; Consultant, Hamamatsu; Speaker, Hologic
  • George Netto: Stock Ownership, "Thrive Early Detection Corp" (CanserSEEK, UroSEEK, PapSEEK); Advisory Board Member, Genentech; Patent, TERT Promoter Mutations in Urothelial Neoplasia

The following faculty reported no relevant financial relationships: Thomas Brenn, Julia Bridge, John Eble, Rohit Mehra, Peter Sadow, Russell Vang

The following IM Coordinator who planned and reviewed content for this activity reported no relevant financial relationships: Steven Billings, Laura Lamps, David Kaminsky

USCAP staff associated with the development of content for this activity reported no relevant financial relationships.

To earn CME credit, all learners must complete the evaluation. View and print your certificate by clicking here .

Buy the entire Modern Pathology course and get a great discount!

Not A Member? Click Here